Werewolf

TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Boston Scientific, Werewolf, Growth, Genentech, Strategic management, CFO, Business, Novartis, Trustee, Patient, Chairperson, Tuck School of Business, CBO, Sale, Business development, Acquisition, University, IPO, Belharra, Columbia Law School, Doctor of Philosophy, Senior, MBA, Clinical trial, Therapy, Guidant, DePauw University, Claremont McKenna College, Drug resistance, Celgene, FDA, Economics, Corporation, Management

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
  • "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry.
  • Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership.

Black Kite Unveils Industry’s First Monthly Ransomware Dashboards

Retrieved on: 
Wednesday, January 24, 2024
RDP, Research, DNS, Intelligence, Werewolf, Risk, RSI, Black kite, Machine learning, Motivation, SMB, Cryptocurrency

The resource provides data, graphs, trends, and key insights from Black Kite’s threat intelligence team about the top ransomware groups, their victims, and attack patterns.

Key Points: 
  • The resource provides data, graphs, trends, and key insights from Black Kite’s threat intelligence team about the top ransomware groups, their victims, and attack patterns.
  • Black Kite also analyzes the top ransomware indicators to identify common vulnerabilities exploited by active ransomware groups, and using data and machine learning, Black Kite’s Ransomware Susceptibility Index (RSI) paints a comprehensive picture of the industry-specific cyber-risks that organizations face each month.
  • “Since recently entering the scene, the WereWolves ransomware group has targeted 26 victims in the U.S., Europe, and Russia,” said Ferhat Dikbiyik, head of research at Black Kite.
  • To see Black Kite’s latest ransomware data, visit the December report landing page , or view data from the last six months on the Ransomware Reports page.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Giant, Melanoma, Werewolf, Book, Immunotherapy, SITC, Kidney cancer, Society, Therapy, Biopharmaceutical, Georgetown University Medical Center, Harvard Medical School, Committee, Pharmaceutical industry

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
  • “Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy.
  • I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules,” said Dan Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics.
  • He has published over 500 scientific and review articles, co-edited five books, and given over 800 lectures worldwide.

NYX Professional Makeup Announces "Mon-Star Bash" Halloween Campaign Inspired By Universal Monsters

Retrieved on: 
Monday, September 18, 2023
Universal Pictures, Music, Bride, Gen, DJ, Werewolf, NYX Professional Makeup, SFX, NYX, Ulta Beauty, Generation Z, Gold, Collection, Face, Personality, Universal, UGC, Character, Roblox, Social media, Universal Classic Monsters, Fireworks, Cosmetics

LOS ANGELES, Sept. 18, 2023 /PRNewswire/ -- NYX Professional Makeup announced today the launch of the limited-edition "Mon-Star Bash" Halloween campaign inspired by Universal Pictures' classic Universal Monsters, starring a diverse cast of rising Gen Z stars.

Key Points: 
  • LOS ANGELES, Sept. 18, 2023 /PRNewswire/ -- NYX Professional Makeup announced today the launch of the limited-edition "Mon-Star Bash" Halloween campaign inspired by Universal Pictures' classic Universal Monsters, starring a diverse cast of rising Gen Z stars.
  • Through SFX artistry and entertainment, the campaign aims to reintroduce the iconic Monsters of yesterday to a new generation for Halloween.
  • NYX Professional Makeup, known for their elaborate and unique Halloween initiatives, has once again partnered with globally renowned makeup artist, Mimi Choi, to create five exclusive and reimagined looks with a modernized twist.
  • Additionally, NYX Professional Makeup will continue to expand its ongoing presence within Roblox, partnering with ULTA Beauty's ULTAverse on the platform.

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Insurance, Therapy, Non-Hodgkin lymphoma, CAS (formerly Chemical Abstracts Service), Cancer, Pharmacokinetics, Research, Immunotherapy, Investigational New Drug, Patient, Jazz Pharmaceuticals, Pembrolizumab, Tumor microenvironment, IND, Safety, Pharmaceutical industry, Vaccine, Werewolf

WATERTOWN, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Financial Results for the Second Quarter of 2023:
    Cash position: As of June 30, 2023, cash and cash equivalents were $137.5 million, compared to $147.9 million as of March 31, 2023.
  • Collaboration revenue: Collaboration revenue was $8.1 million for the second quarter of 2023, compared to $4.1 million for the same period in 2022.
  • Research and development expenses: Research and development expenses were $9.6 million for the second quarter of 2023, compared to $13.9 million for the same period in 2022.
  • Net loss: Net loss was $5.1 million for the second quarter of 2023, compared to $14.6 million for the same period in 2022.

Game On, Lionesses Style: Asmodee's Football-Inspired Board Games

Retrieved on: 
Friday, July 21, 2023
Captain, Food, Travel, World cup, Cunning, Woman, Mind, 2015 FIVB Volleyball Men's World Cup, Brainbox, England women's national football team, Cheese, Observation, Photosynthesis, City, Family, Family Game Night (game show), Deception, Football, Entertainment, Sport, Video game, Dobble, Bananagrams, Werewolf, Asmodee

With these exciting game recommendations, channel the spirit of the Lionesses and hone football prowess right from the living room.

Key Points: 
  • With these exciting game recommendations, channel the spirit of the Lionesses and hone football prowess right from the living room.
  • Werewolves - The Cunning Playmaker:
    Unleash the cunning playmaker within as you delve into the intense game of Werewolves, played by the Men's World Cup squad in Qatar.
  • Pandemic - The Team Captain:
    Emerge as the team captain, leading your elite squad to victory in Pandemic, a cooperative game of strategy and teamwork.
  • CATAN - The Resourceful Manager:
    Become the resourceful manager of the team in CATAN, a game of dominance and strategy.

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Online, Lymphoma, IL-12, AACR, Therapy, Non-Hodgkin lymphoma, Therapeutic index, Cancer, Toxicity, Research, Immunotherapy, Cancer Immunology Research, PacWest Bancorp, Patient, Mouse, Jazz Pharmaceuticals, Neoplasm, Lymphocyte, Pembrolizumab, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Werewolf

WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • “In the first quarter, Werewolf has focused on execution by progressing our INDUKINE pipeline and enrolling ongoing first-in-human clinical trials for our lead programs, WTX-124 and WTX-330.
  • Reid is a founding member of the Werewolf Executive Team and has been instrumental in leading and advancing all aspects of organizational operations.
  • Financial Results for the First Quarter of 2023:
    Cash position: As of March 31, 2023, cash and cash equivalents were $147.9 million, compared to $129.3 million as of December 31, 2022.
  • Net loss: Net loss was $12.0 million for the first quarter of 2023, compared to $15.3 million for the same period in 2022.

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

Retrieved on: 
Friday, February 24, 2023
Safety, Therapy, Cancer, Non-Hodgkin lymphoma, Toxic leukoencephalopathy, Trial of the century, Interleukin 12, Neoplasm, Tumor microenvironment, Immunity, Cytokine, Werewolf, Lymphoma, Pharmaceutical industry, Vaccine, Patient

WATERTOWN, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330, the Company’s lead INDUKINETM molecule targeting Interleukin-12 (IL-12). The Phase 1 clinical trial is a first-in-human, multi-center, open-label trial that will evaluate WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved.

Key Points: 
  • “Dosing the first patient in our Phase 1 trial of WTX-330 marks the second INDUKINE molecule arising from our PREDATORTM protein engineering platform to enter the clinic.
  • Our continued transition into a clinical stage company comes at an exciting time for Werewolf following the initiation of a Phase 1/1b clinical study of WTX-124 last year,” said Daniel J. Hicklin, Ph.D., Werewolf’s Founder and Chief Executive Officer.
  • In preclinical studies, WTX-330 exhibited excellent anti-tumor activity and a favorable pharmacokinetic and tolerability profile.
  • For additional information about the trial, please visit www.clinicaltrials.gov using the Identifier: NCT05678998

The Pack is Back! Teen Wolf: The Movie Roars into the Metaverse

Retrieved on: 
Wednesday, December 21, 2022
Metaverse, Wild 'n Out, MTV, Character, Social media, Teen Wolf, VMA, Paramount, SLGG, Marketing, MTV Video Music Awards, Human, Wild, MGM, NPC, Video game, Film, Minecraft, Super League, Werewolf, Wolf, Hellhound, Banshee

Those assigned as villains attempt to capture all of the wolves before they can make their dramatic escape.

Key Points: 
  • Those assigned as villains attempt to capture all of the wolves before they can make their dramatic escape.
  • "We're looking forward to seeing how much Teen Wolf fans will enjoy this engaging and immersive gameplay experience."
  • In addition, one and a half million fans cast their votes for the first ever Best Metaverse Performance Award.
  • For more information about Paramount+ and TEEN WOLF: THE MOVIE, please visit paramountplus.com , Follow @ParamountPlus on all social platforms and Teen Wolf’s Twitter , Instagram , Facebook and TikTok .

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Molecule, GLOBE, IND, Lymphoma, Abstract, U.S. Securities and Exchange Commission, Toxic epidermal necrolysis, Tumor microenvironment, IL-12, Immunotherapy, Neoplasm, Private Securities Litigation Reform Act, Mouse, COVID-19, Half-life, Therapy, SEC, SITC, Company, Lymphocyte, Werewolf, Terminology, NK, Wilms' tumor, TH1, TME, Security (finance), Interleukin, Society, Phenotype, FDA, Pharmaceutical industry, Medical imaging, Vaccine, Cancer

WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will present preclinical data on mWTX-330, a mouse surrogate of its interleukin-12 (“IL-12”) INDUKINETM product candidate, WTX-330, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) being held November 8-12, 2022, in Boston, and virtually.

Key Points: 
  • Study data demonstrate that systemic administration of mWTX-330, a mouse surrogate INDUKINE molecule, generates potent anti-tumor activity in a cleavage-dependent manner and protective memory against re-challenge in multiple murine syngeneic tumor models.
  • Additionally, the data showed substantial infiltration and robust IL-12 signaling in intratumoral CD8+ T cells.
  • This morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330.
  • Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer.